|Bid||1,850.00 x 16300|
|Ask||2,350.00 x 34600|
|Day's range||1,931.00 - 1,971.00|
|52-week range||1,575.00 - 2,703.00|
|PE ratio (TTM)||29.37|
|Dividend & yield||0.22 (0.93%)|
|1y target est||N/A|
GlaxoSmithKline (Other OTC: GLAXF - news) 's new chief executive aims to improve returns in drug development, and wants fewer but bigger new medicine launches. In her first comments since taking over on April 1, Emma Walmsley, 47, said on Wednesday that her priority was the pharmaceuticals unit, where she wants commercial considerations to be given greater weight in early investment decisions. "We'd like to have probably fewer and more focused priorities, to have bigger launches," she told reporters, after announcing first-quarter results, adding this would involve tough choices and the closure of some research programmes.
GlaxoSmithKline's new chief executive reported slightly better than expected first-quarter results on Wednesday, keeping the drugmaker on track to hit financial targets in 2017 as it braces for generic ...
Shares surged 7.6% on the news, but the devil’s in the details.